From The Editor - TON March 2018

TON - March 2018, Vol 11, No 1 - From the Editors
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

 

From The Editor - TON March 2018

The March issue of The Oncology Nurse-APN/PA is full of important news and updates for oncology nurses. In this issue, we feature a profile of the Taussig Cancer Center, Cleveland Clinic, OH, where, in my capacity as a nurse practitioner in the Department of Hematologic Oncology and Blood Disorders, my primary role is to diagnose and manage patients with multiple myeloma, amyloidosis, and other hematologic disorders (view here).

The Taussig Cancer Center is the number 1 cancer center in Ohio, and the number 2 hospital in the United States, according to the U.S. News & World Report ranking. This status allows us to attract cases that are difficult to diagnose, including patients with amyloidosis, which is an extremely rare condition. Our amyloidosis partners work with other specialists in the management of amyloidosis to provide comprehensive care.

Other valuable insights that can be gleaned from articles in this issue include the dismal results of a recent study analyzing the use of palliative care services among patients with hematologic malignancies (view here); the potential for taselisib, a phosphoinositide-3-kinase inhibitor, to shrink tumors in patients with estrogen receptor–positive, HER2-negative early breast cancer (view here) , and some noteworthy statistics pertaining to cervical cancer, which occurs in approximately 12,000 women in the United States each year (view here).

We also feature a profile of Laura Mulderrig, BSN, RN, OCN, a nurse in the clinical research unit of Fox Chase Cancer Center, Philadelphia, PA, who was presented with the 2017 Oncology Nurse Excellence (ONE) award at the Academy of Oncology Nurse & Patient Navigators 8th Annual Navigation & Survivorship Conference, which took place in Orlando, FL, November 16-19, 2017 (view here).

At the 59th Annual Meeting and Exposition of the American Society of Hematology, David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, presented data from a recent analysis that he and his colleagues conducted of a commercial claims database (view here). The results suggest that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems.

“The use of novel multiple myeloma drugs has been associated with improved therapeutic outcomes and survival, but the disease continues to pose a significant economic burden. Evaluating the economic implications and outcomes of available treatments is important to improve efficiency of care,” Mr Merola said.

At the same meeting, Mahesh Swaminathan, MD, Leukemia Fellow, M.D. Anderson Cancer Center, Houston, TX presented interim data from an ongoing clinical trial demonstrating that the combination of the investigational drug quizartinib plus azacitidine or low-dose cytarabine has substantial activity in patients with myeloid leukemias and FLT3 mutations (view here).

“The treatment was associated with a low rate of early deaths, with a 60-day mortality rate of only 5% in the azacitidine arm and 0% in the low-dose cytarabine arm,” Dr Swaminathan told attendees.

This issue also includes articles on the challenges associated with the adverse side effects of oral cancer drugs (view here), new criteria for inherited prostate cancer genetic testing (view here), and what to say—or not to say—to patients with cancer during their cancer journey, as told from the perspective of Brianne Joseph, LPI, a breast cancer survivor and award-winning author of Punk Azz Cancer, How Dare You! (view here).

As always, we hope you will enjoy this issue of TON and look forward to receiving your feedback. You can contact us via e-mail at info@TheOncologyNurse.com.

Related Items
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2019, Vol 12, No 2 published on May 12, 2019 in From the Editors
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in From the Editors
From the Editor - TOP November 2018
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in From the Editors
From the Editor - TON September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in From the Editors
From the Editor - TOP August 2018
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in From the Editors
From the Editor - TON July 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in From the Editors
From The Editors - TOP November 2017
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Cancer Center Profile
From the Editors
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in From the Editors
Last modified: June 11, 2018